Underutilization of Combined-Modality Therapy in Limited-Stage Small Cell Lung Cancer—Reply

In Reply We are pleased by the interest of Alcorn and colleagues in our study looking at barriers to combined-modality therapy for the initial management of limited-stage small cell lung cancer (LS-SCLC) in the National Cancer Database (NCDB). With current efforts to retract the 340b and Medicaid Discount Program, we thank Alcorn et al for their call to action to address the large number of patients not receiving standard combined-modality therapy for LS-SCLC seen in the NCDB. As proposed in our article, we agree that additional analyses are urgently needed to further interrogate the causes of heterogeneous care delivery for LS-SCLC.

https://ift.tt/2vpWPr8